140 related articles for article (PubMed ID: 24470513)
1. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
Szkandera J; Pichler M; Absenger G; Stotz M; Weissmueller M; Samonigg H; Asslaber M; Lax S; Leitner G; Winder T; Renner W; Gerger A
Clin Cancer Res; 2014 Mar; 20(6):1687-97. PubMed ID: 24470513
[TBL] [Abstract][Full Text] [Related]
2. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
Páez D; Gerger A; Zhang W; Yang D; Labonte MJ; Benhanim L; Kahn M; Lenz F; Lenz C; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
Pharmacogenomics J; 2014 Apr; 14(2):142-50. PubMed ID: 23817222
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
4. Lymphovascular Invasion and Perineural Invasion Negatively Impact Overall Survival for Stage II Adenocarcinoma of the Colon.
Skancke M; Arnott SM; Amdur RL; Siegel RS; Obias VJ; Umapathi BA
Dis Colon Rectum; 2019 Feb; 62(2):181-188. PubMed ID: 30640833
[TBL] [Abstract][Full Text] [Related]
5. Common cancer stem cell gene variants predict colon cancer recurrence.
Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
[TBL] [Abstract][Full Text] [Related]
6. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
[TBL] [Abstract][Full Text] [Related]
7. Expression of GLI1 correlates with expression of lymphangiogenesis proteins, vascular endothelial growth factor C and vascular endothelial growth factor receptor 3, in colorectal cancer.
Hong KD; Lee Y; Kim BH; Lee SI; Moon HY
Am Surg; 2013 Feb; 79(2):198-204. PubMed ID: 23336661
[TBL] [Abstract][Full Text] [Related]
8. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
9. GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
Dunjic M; Lukic N; Djordjevic B; Uzelac B; Ostojic N; Supic G
Melanoma Res; 2022 Feb; 32(1):11-17. PubMed ID: 34939981
[TBL] [Abstract][Full Text] [Related]
10. Expression of the GLI family genes is associated with tumor progression in advanced lung adenocarcinoma.
Ishikawa M; Sonobe M; Imamura N; Sowa T; Shikuma K; Date H
World J Surg Oncol; 2014 Aug; 12():253. PubMed ID: 25103784
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of hedgehog signaling pathway in patients with colon cancer.
Xu M; Li X; Liu T; Leng A; Zhang G
Med Oncol; 2012 Jun; 29(2):1010-6. PubMed ID: 21424326
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
[TBL] [Abstract][Full Text] [Related]
13. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Sebio A; Matsusaka S; Zhang W; Yang D; Ning Y; Stremitzer S; Stintzing S; Sunakawa Y; Yamauchi S; Fujimoto Y; Ueno M; Lenz HJ
Pharmacogenomics J; 2016 Aug; 16(4):312-9. PubMed ID: 26370619
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
15. Association of common gene variants in vitamin D modulating genes and colon cancer recurrence.
Szkandera J; Absenger G; Pichler M; Stotz M; Langsenlehner T; Samonigg H; Renner W; Gerger A
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1457-64. PubMed ID: 23793229
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary.
Fotopoulos G; Gousia A; Bareta E; Koumpis E; Chrisafi S; Bobos M; Malamou-Mitsi V; Fountzilas G; Pavlidis N; Pentheroudakis G
Eur J Clin Invest; 2015 Nov; 45(11):1145-52. PubMed ID: 26269154
[TBL] [Abstract][Full Text] [Related]
17. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
19. Aberrant activation of hedgehog signaling pathway contributes to endometrial carcinogenesis through beta-catenin.
Liao X; Siu MK; Au CW; Chan QK; Chan HY; Wong ES; Ip PP; Ngan HY; Cheung AN
Mod Pathol; 2009 Jun; 22(6):839-47. PubMed ID: 19329935
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
